Xin Wang, Rui Sun, Yushu Huang, Yisi Yan, Miaomiao Gao, Dan-Ni Wang, Diwa Koirala, Da-Wei Li and Chun Hu Pages 836 - 842 ( 7 )
Estrogen receptors (ERs) are members of a superfamily of ligand-modulated nuclear receptors, which have been associated with an increased risk of cardiovascular diseases and breast cancer. Based on molecular docking studies, 1,4-dihydrothieno[3’,2’:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide derivatives as estrogen receptor inhibitors with a new scaffold , have been synthesized and tested for the antitumor activity on the ER expressing (ER dependent) human MCF-7 breast cancer cell line. According to the biological activity evaluation, compound 6a demonstrated the most potent antiproliferative activity (relative inhibitory rate: 100%). Several of these compounds exhibited moderate antitumor activity and worthy of further modification to obtain more potent anticancer candidate drugs.
Anti-tumor activity, heterocycle, docking, synthesis.
Key Laboratory of Structure- Based Drug Design & Discovery, Ministry of Education, China, Shenyang Pharmaceutical University, Shenyang 110016, China.